Minerva Neurosciences, Inc.: BALYASNY ASSET MANAGEMENT L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Balyasny Asset Management L.P. amended its Schedule 13G stake filing for Minerva Neurosciences, Inc., according to SEC accession 0001172661-26-005051. The filing updates the asset manager's previously reported beneficial ownership position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed when a passive investor's stake crosses reporting thresholds or otherwise changes materially. The revised disclosure matters because it clarifies Balyasny's current holdings in Minerva, a stock sensitive to shifts in institutional ownership. Investors will watch for further 13G or 13D filings to gauge whether Balyasny's position continues to change.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Balyasny Asset Management L.P., Minerva Neurosciences, Inc.